Patents by Inventor Lisa Matzen

Lisa Matzen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT 1B/1D ligands
    Publication number: 20050176730
    Abstract: Amide and urea derivatives of the formula I R1—(CH2)n—(Y)q-(Z)r-CO—NH—R2 ??(I) in which R1, n, Y, q, Z, r and R2 have the meanings indicated in claim 1, are potent 5-HT1B/1D antagonists and exhibit 5-HT reuptake-inhibiting actions and are suitable for the treatment and prophylaxis of anxiety states, depressions, schizophrenia, compulsive ideas, tardive dyskinesias, learning disorders, age-dependent memory disorders, for positively affecting obsessive-compulsive behaviour (OCD), and also for the treatment and for the control of the sequelae of cerebral infarcts such as stroke and cerebral ischaemias.
    Type: Application
    Filed: July 2, 2003
    Publication date: August 11, 2005
    Applicant: MERCK PATENT GMBH
    Inventors: Christoph Van Amsterdam, Hartmut Greiner, Henning Boettcher, Gerd Bartoszyk, Juergen Harting, Lisa Matzen, Wilfried Rautenberg
  • Amide and urea derivatives as 5-HT reuptake inhibitors and as5-HT1B/1D ligands
    Publication number: 20030064995
    Abstract: Amide and urea derivatives of the formula I
    Type: Application
    Filed: September 10, 2002
    Publication date: April 3, 2003
    Applicant: MERCK PATENT GMBH
    Inventors: Christoph Van Amsterdam, Hartmut Greiner, Henning Boettcher, Gerd Bartoszyk, Juergen Harting, Lisa Matzen, Wilfried Rautenberg
  • Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT1B/1D ligands
    Patent number: 6509340
    Abstract: Amide and urea derivatives of the formula I R1—(CH2)n—(Y)q—(Z)r—CO—NH—R2  (I) in which R1, n, Y, q, Z, r and R2 have the meanings indicated in Claim 1, are potent 5-HT1B/1D antagonists and exhibit 5-HT reuptake-inhibiting actions and are suitable for the treatment and prophylaxis of anxiety states, depressions, schizophrenia, compulsive ideas, tardive dyskinesias, learning disorders, age-dependent memory disorders, for positively affecting obsessive-compulsive behaviour (OCD), and also for the treatment and for the control of the sequelae of cerebral infarcts such as stroke and cerebral ischaemias.
    Type: Grant
    Filed: October 3, 2001
    Date of Patent: January 21, 2003
    Assignee: Merck Patentgesellschaft
    Inventors: Christoph Van Amsterdam, Hartmut Greiner, Henning Boettcher, Gerd Bartoszyk, Juergen Harting, Lisa Matzen, Wilfried Rautenberg